Opportunity Information: Apply for PA 14 069
Apply for PA 14 069
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Neurobiology of Migraine (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.173 Research Related to Deafness and Communication Disorders 93.273 Alcohol Research Programs 93.313 NIH Office of Research on Womens Health 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
- This funding opportunity was created on Jan 13, 2014 and posted on Jan 13, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Independent school districts State governments City or township governments Small businesses Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education County governments Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Neurobiology of Migraine (R21) funding opportunity (PA-14-069) was a National Institutes of Health (NIH) discretionary grant announcement led by the National Institute of Neurological Disorders and Stroke (NINDS) in partnership with the NIH Pain Consortium. It called for Exploratory/Developmental Research Grant (R21) applications focused on migraine, with an emphasis on novel, high-impact ideas that could quickly move the field forward. The core purpose was to support innovative projects that clarify the biological mechanisms behind migraine, improve understanding of why some people are more susceptible than others, and identify new ways to treat migraine attacks and prevent them over the longer term.
Scientifically, the FOA targeted research that digs into migraine pathophysiology and the processes that drive susceptibility, onset, and progression. A major theme was mechanism: proposals were expected to go beyond describing migraine-associated phenomena and instead test fresh hypotheses about how migraine is generated and sustained at genetic, molecular, cellular, circuit, systems, and whole-person levels. The opportunity also highlighted the importance of integrating multiple dimensions of risk and disease expression, explicitly naming genetic, physiological, biopsychosocial, and environmental influences. In practice, this meant that strong applications could examine how inherited variation interacts with neurobiological processes, how stress and behavioral factors shape migraine expression, or how environmental triggers and exposures alter migraine thresholds and trajectories. The FOA also encouraged work that could uncover or validate new therapeutic targets and evaluate potential therapies, including approaches aimed at both acute attack management and prevention.
Because this was an R21 mechanism, the program was geared toward early-stage, exploratory studies rather than large, fully mature programs of research. R21 projects are generally expected to be innovative and potentially transformative, often supporting proof-of-concept experiments, development of new models or methods, or generation of key preliminary data that can justify a later, larger application. The award ceiling listed for this opportunity was $200,000, and there was no cost sharing or matching requirement, reducing barriers for applicants who might not have institutional funds to contribute.
Eligibility was broad and included many types of domestic and non-domestic organizations. Eligible applicants included public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including 501(c)(3) and other nonprofit statuses), for-profit organizations (including small businesses and other for-profit entities), and a wide range of government bodies such as state, county, city/township, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The FOA also explicitly included Native American tribal governments (federally recognized), as well as tribal organizations and tribal governments that are not federally recognized, along with tribally controlled colleges and universities. It also welcomed applications from minority-serving institutions and related entities, including HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, and AANAPISIs, as well as faith-based and community-based organizations. Importantly, foreign organizations and foreign institutions were eligible to apply, and non-U.S. components of U.S. organizations were eligible, with foreign components allowed consistent with NIH policy.
From an administrative standpoint, the FOA was posted on January 13, 2014, with the original and current closing date listed as May 7, 2017, and an archive date of June 7, 2017, meaning it is no longer active for new submissions under that specific announcement. The activity category was Health, and it was associated with multiple CFDA program areas (including neurosciences and neurological disorders and related research domains). Applicants seeking the full text and official requirements were directed to the NIH posting at the provided grants.nih.gov link, with NIH Office of Extramural Research (OER) webmaster contacts listed for access or linking problems.
Overall, this opportunity was designed to push migraine research toward clearer mechanistic explanations and more actionable therapeutic directions by funding creative, exploratory R21 projects that connect biology with real-world influences on migraine and that open new paths for treating and preventing this highly prevalent and disabling neurological condition.
Frequently Asked Questions (FAQs): The Neurobiology of Migraine (R21) (PA-14-069)
1) What is the “Neurobiology of Migraine (R21)†funding opportunity?
It was a National Institutes of Health (NIH) discretionary Funding Opportunity Announcement (FOA) titled The Neurobiology of Migraine (R21), identified as PA-14-069. The FOA invited applications under the Exploratory/Developmental Research Grant (R21) mechanism and focused on migraine research.
2) Which NIH institute led this opportunity?
The opportunity was led by the National Institute of Neurological Disorders and Stroke (NINDS) in partnership with the NIH Pain Consortium.
3) What was the main purpose of this FOA?
The core purpose was to support innovative, exploratory projects that clarify the biological mechanisms of migraine, improve understanding of susceptibility (why some individuals are more affected than others), and identify new approaches to treat migraine attacks and prevent migraine over the longer term.
4) What kind of research did the FOA prioritize?
The FOA prioritized research on migraine pathophysiology and the processes that drive susceptibility, onset, and progression. A major emphasis was on mechanistic work: projects were expected to test new hypotheses about how migraine is generated and sustained.
5) What does “mechanistic†mean in the context of this FOA?
Within this FOA, “mechanistic†meant going beyond describing migraine-associated phenomena and instead testing fresh, explanatory hypotheses about how migraine works across biological levels (for example: genetic, molecular, cellular, circuit, systems, and whole-person levels).
6) What biological or analytical levels were explicitly mentioned as relevant?
The FOA explicitly referenced genetic, molecular, cellular, circuit, systems, and whole-person levels as potential levels at which migraine mechanisms could be investigated.
7) Did the FOA encourage integrating non-biological influences on migraine?
Yes. The FOA highlighted integrating multiple dimensions of risk and disease expression, explicitly naming genetic, physiological, biopsychosocial, and environmental influences.
8) What are examples of integrated research angles that would align with the FOA’s emphasis?
Examples described in the FOA’s framing included studying how inherited variation interacts with neurobiological processes, how stress and behavioral factors shape migraine expression, and how environmental triggers or exposures alter migraine thresholds and trajectories.
9) Was therapy development or target identification within scope?
Yes. The FOA encouraged research that could uncover or validate new therapeutic targets and evaluate potential therapies, including approaches aimed at both acute attack management and longer-term prevention.
10) What grant mechanism was used, and what does it imply about project maturity?
The FOA used the NIH R21 (Exploratory/Developmental Research Grant) mechanism. This mechanism is geared toward early-stage, exploratory studies rather than large, fully mature research programs.
11) What types of projects are typically suitable for an R21 under this FOA?
As described, R21 projects are often innovative and potentially transformative and may support proof-of-concept experiments, development of new models or methods, or generation of key preliminary data that can support a later, larger application.
12) What was the award ceiling for this opportunity?
The award ceiling listed for this opportunity was $200,000.
13) Was cost sharing or matching required?
No. The FOA stated there was no cost sharing or matching requirement.
14) What types of organizations were eligible to apply?
Eligibility was broad and included many domestic and non-domestic organizations. Eligible applicants included public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including 501(c)(3) and other nonprofit statuses), and for-profit organizations (including small businesses and other for-profit entities).
15) Were government entities eligible applicants?
Yes. The FOA listed a wide range of eligible government bodies, including state, county, city/township, and special district governments, as well as independent school districts and public housing authorities/Indian housing authorities.
16) Were tribal governments and tribal organizations eligible?
Yes. The FOA explicitly included Native American tribal governments (federally recognized), as well as tribal organizations and tribal governments that are not federally recognized. It also included tribally controlled colleges and universities.
17) Did the FOA explicitly welcome minority-serving institutions?
Yes. It welcomed applications from minority-serving institutions and related entities, including HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, and AANAPISIs.
18) Were faith-based and community-based organizations eligible?
Yes. The FOA explicitly included faith-based and community-based organizations among eligible applicants.
19) Were foreign organizations eligible to apply?
Yes. Foreign organizations and foreign institutions were eligible to apply, and non-U.S. components of U.S. organizations were eligible. Foreign components were allowed consistent with NIH policy.
20) When was the FOA posted, and what were the closing and archive dates?
The FOA was posted on January 13, 2014. The original and current closing date was listed as May 7, 2017. The archive date was June 7, 2017.
21) Is this specific funding opportunity still open for new submissions?
No. Based on the closing date and archive date provided, the PA-14-069 announcement is no longer active for new submissions under that specific announcement.
22) What was the activity category associated with this FOA?
The activity category was Health.
23) Was the opportunity tied to specific CFDA program areas?
Yes. It was associated with multiple CFDA program areas, including neurosciences and neurological disorders and related research domains.
24) Where were applicants directed for the official FOA text and requirements?
Applicants were directed to the NIH posting on grants.nih.gov (via the provided link in the announcement) for the full text and official requirements.
25) Who was listed for help with access or linking problems?
NIH Office of Extramural Research (OER) webmaster contacts were listed for access or linking problems.
Browse more opportunities from the same category: Health
Next opportunity: Every Day Counts Initiative Request for Information
Previous opportunity: Neurobiology of Migraine (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 14 069
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 14 069) also looked into and applied for these:
| Funding Opportunity |
|---|
| State Public Health Approaches to Improving Arthritis Outcomes Apply for CDC RFA DP12 121003CONT14 Funding Number: CDC RFA DP12 121003CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NIA Limited Competition Renewal of, and Revisions to, the Alzheimers Disease Genetics Consortium (U01) Apply for PAR 14 070 Funding Number: PAR 14 070 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Early Intervention Services (EIS Program) Existing Geographic Service Areas (EISEGA) Apply for HRSA 14 117 Funding Number: HRSA 14 117 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Resource and Technical Assistance Center for HIV Prevention and Care for Black Men who Have Sex with Men (Black MSM) Cooperative Agreement Apply for HRSA 14 106 Funding Number: HRSA 14 106 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,500,000 |
| Shared Instrumentation Grant Program (S10) Apply for PAR 14 073 Funding Number: PAR 14 073 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition to Develop a BrainSpan RNA seq Browser (R24) Apply for RFA MH 15 100 Funding Number: RFA MH 15 100 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alzheimers Disease Research Centers (P50) Apply for RFA AG 15 002 Funding Number: RFA AG 15 002 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Alzheimers Disease Core Centers (P30) Apply for RFA AG 15 001 Funding Number: RFA AG 15 001 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Poison Center Support and Enhancement Apply for HRSA 14 016 Funding Number: HRSA 14 016 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Supporting Healthy Start Performance Project Apply for HRSA 14 042 Funding Number: HRSA 14 042 Agency: Health Resources and Services Administration Category: Health Funding Amount: $2,000,000 |
| Service Area Competition Additional Area (SAC AA) DC, FL, GA, ID, IL, KS, MO, MT, NY, OR, PA Apply for HRSA 14 116 Funding Number: HRSA 14 116 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Strengthening National Capacity in Malaria and Other Infectious Disease Operations Research Apply for RFA GH 14 003 Funding Number: RFA GH 14 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,250,000 |
| Reimbursement of Travel and Subsistence Expenses for Living Organ Donation Apply for HRSA 14 015 Funding Number: HRSA 14 015 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| A Creutzfeldt Jakob Disease (CJD) Lookback Study Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt Jakob Disease Apply for RFA CK 14 005 Funding Number: RFA CK 14 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $76,000 |
| NIH Directors Biomedical Research Workforce Innovation Award Broadening Experiences in Scientific Training (BEST) (DP7) Apply for RFA RM 13 019 Funding Number: RFA RM 13 019 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Community Health Projects Related to Contamination at Brownfield/Land Reuse Sites (ATSDR CHPs) Apply for CDC RFA TS14 1404 Funding Number: CDC RFA TS14 1404 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $150,000 |
| Secretarys Minority AIDS Initiative Funding to Increase HIV Prevention and Care Service Delivery among Health Centers Serving High HIV Prevalence Jurisdictions Apply for CDC RFA PS14 1410 Funding Number: CDC RFA PS14 1410 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $850,000 |
| Kyrgyzstan TB Program Apply for RFA 176 14 000005 Funding Number: RFA 176 14 000005 Agency: Kazakhstan USAID Almaty Category: Health Funding Amount: $12,800,000 |
| Well Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) Program Apply for CDC RFA DP13 130202CONT14 Funding Number: CDC RFA DP13 130202CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Notification of Request for comments on potential RFA for implementation of the Integrated Family Health Program (IFHP) II in Ethiopia Apply for RFA 663 14 000002 Funding Number: RFA 663 14 000002 Agency: Ethiopia USAID Addis Ababa Category: Health Funding Amount: $75,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 069", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.